p63 expression correlates with sensitivity to the Eg5 inhibitor AZD4877 in bladder cancer cells

Cancer Biology and Therapy

Volumn 13, Issue 7, 2012, Pages 477-486

  Marquis, Lauren ^a,b   Tran, Mai ^a,b   Choi, Woonyoung ^a   Lee, I Ling ^a   Huszar, Dennis ^c   Siefker Radtke, Arlene ^a   Dinney, Colin P ^a   McConkey, David J ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Np63; Apoptosis; C myc; Gene expression profiling

Indexed keywords

ANTIMITOTIC AGENT; AZD 4877; CISPLATIN; DOCETAXEL; GEMCITABINE; KINESIN 5; MYC PROTEIN; PROTEIN P63; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG SENSITIVITY; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KINESIN; PROTO-ONCOGENE PROTEINS C-MYC; PYRIMIDINONES; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 84861147306     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.19590     Document Type: Article

References (53)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300; PMID:20610543; http://dx.doi.org/10.3322/caac.20073.
2. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar- Eli M, Adam L, et al. Focus on bladder cancer. Cancer Cell 2004; 6:111-6; PMID:15324694; http://dx.doi. org/10.1016/j.ccr.2004.08.002.
3. Galsky MD. The role of taxanes in the management of bladder cancer. Oncologist 2005; 10:792-8; PMID:16314289; http://dx.doi.org/10.1634/ theoncologist. 10-10-792.
4. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4:253-65; PMID:15057285; http://dx.doi.org/10.1038/nrc1317.
5. Sudakin V, Yen TJ. Targeting mitosis for anti-cancer therapy. BioDrugs 2007; 21:225-33; PMID:17628120; http://dx.doi.org/10.2165/00063030-200721040- 00003.
6. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002; 249:9- 17; PMID:11954874; http://dx.doi.org/10.1007/ PL00007853.
7. Zhang Y, Xu W. Progress on kinesin spindle protein inhibitors as anti-cancer agents. Anticancer Agents Med Chem 2008; 8:698-704; PMID:18690830.
8. Tao W. The mitotic checkpoint in cancer therapy. Cell Cycle 2005; 4:1495-9; PMID:16258280; http:// dx.doi.org/10.4161/cc.4.11.2130.
9. Sawin KE, LeGuellec K, Philippe M, Mitchison TJ. Mitotic spindle organization by a plus-end-directed microtubule motor. Nature 1992; 359:540-3; PMID:1406972; http://dx.doi.org/10.1038/359540a0.
10. cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 1995; 83:1159-69; PMID:8548803; http://dx.doi. org/10.1016/0092-8674(95) 90142-6.
11. Lee EA, Keutmann MK, Dowling ML, Harris E, Chan G, Kao GD. Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells. Mol Cancer Ther 2004; 3:661-9; PMID:15210851.
12. Masuda A, Maeno K, Nakagawa T, Saito H, Takahashi T. Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. Am J Pathol 2003; 163:1109-16; PMID:12937152; http://dx.doi.org/10.1016/S0002-9440(10)63470-0.
13. Sudo T, Nitta M, Saya H, Ueno NT. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 2004; 64:2502-8; PMID:15059905; http://dx.doi.org/10.1158/0008-5472.CAN-03-2013.
14. Tang C, Willingham MC, Reed JC, Miyashita T, Ray S, Ponnathpur V, et al. High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 1994; 8:1960-9; PMID:7526093.
15. Huang Y, Ibrado AM, Reed JC, Bullock G, Ray S, Tang C, et al. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 1997; 11:253-7; PMID:9009089; http:// dx.doi.org/10.1038/sj.leu.2400557.
16. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997; 272:17118-25; PMID:9202030; http://dx.doi. org/10.1074/jbc.272.27.17118.
17. Cdc2kinase. Mol Cell 1998; 2:581-91; PMID:9844631; http://dx.doi.org/10.1016/S1097-2765(00)80157-4.
18. Chin GM, Herbst R. Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint. Mol Cancer Ther 2006; 5:2580-91; PMID:17041103; http://dx.doi. org/10.1158/1535-7163.MCT- 06-0201.
19. Shi J, Orth JD, Mitchison T. Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Res 2008; 68:3269-76; PMID:18451153; http://dx.doi.org/10.1158/0008-5472.CAN-07-6699.
20. Blanpain C, Fuchs E. p63: revving up epithelial stem-cell potential. Nat Cell Biol 2007; 9:731-3; PMID:17603506; http://dx.doi.org/10.1038/ ncb0707-731.
21. Kurzrock EA, Lieu DK, Degraffenried LA, Chan CW, Isseroff RR. Label-retaining cells of the bladder: candidate urothelial stem cells. Am J Physiol Renal Physiol 2008; 294:1415-21; PMID:18367656; http://dx.doi. org/10.1152/ajprenal.00533.2007.
22. Karni-Schmidt O, Castillo-Martin M, Shen TH, Gladoun N, Domingo-Domenech J, Sanchez-Carbayo M, et al. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol 2011; 178:1350- 60; PMID:21356385; http://dx.doi.org/10.1016/j. ajpath.2010.11.061.
23. Urist MJ, Di Como CJ, Lu ML, Charytonowicz E, Verbel D, Crum CP, et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 2002; 161:1199-206; PMID:12368193; http://dx.doi.org/10.1016/S0002- 9440(10)64396-9.
24. Choi W, Shah JB, Tran M, Svatek R, Marquis L, Lee IL, et al. p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One 2012; 7:30206; PMID:22253920; http://dx.doi.org/10.1371/journal. pone.0030206.
25. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411:342-8; PMID:11357141; http://dx.doi. org/10.1038/35077213.
26. Donaldson KL, Goolsby GL, Wahl AF. Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int J Cancer 1994; 57:847-55; PMID:7911457; http://dx.doi. org/10.1002/ijc.2910570614.
27. Patturajan M, Nomoto S, Sommer M, Fomenkov A, Hibi K, Zangen R, et al. DeltaNp63 induces beta-catenin nuclear accumulation and signaling. Cancer Cell 2002; 1:369-79; PMID:12086851; http://dx.doi. org/10.1016/S1535-6108(02)00057-0.
28. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281:1509- 12; PMID:9727977; http://dx.doi.org/10.1126/science. 281.5382.1509.
29. Yochum GS, Cleland R, Goodman RH. A genomewide screen for beta-catenin binding sites identifies a downstream enhancer element that controls c-Myc gene expression. Mol Cell Biol 2008; 28:7368- 79; PMID:18852287; http://dx.doi.org/ 10.1128/ MCB.00744-08.
30. Yochum GS, Sherrick CM, Macpartlin M, Goodman RH. A beta-catenin/TCF- coordinated chromatin loop at MYC integrates 5' and 3' Wnt responsive enhancers. Proc Natl Acad Sci USA 2010; 107:145- 50; PMID:19966299; http://dx.doi.org/10. 1073/ pnas.0912294107.
31. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69:119-28; PMID:1555236; http://dx.doi.org/10.1016/0092- 8674(92)90123-T.
32. Askew DS, Ashmun RA, Simmons BC, Cleveland JL. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 1991; 6:1915-22; PMID:1923514.
33. Avritscher EB, Cooksley CD, Grossman HB, Sabichi AL, Hamblin L, Dinney CP, et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 2006; 68:549-53; PMID:16979735; http://dx.doi.org/10.1016/j.urology. 2006.03.062.
34. Millikan R, Dinney C, Swanson D, Sweeney P, Ro JY, Smith TL, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 2001; 19:4005-13; PMID:11600601.
35. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349:859-66; PMID:12944571; http:// dx.doi.org/10.1056/NEJMoa022148.
36. Shah JB, McConkey DJ, Dinney CP. New strategies in muscle-invasive bladder cancer: on the road to personalized medicine. Clinical cancer research: an official journal of the American Association for Cancer Research 2011; 17:2608-12.
37. Smith SC, Baras AS, Dancik G, Ru Y, Ding KF, Moskaluk CA, et al. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol 2011; 12:137-43; PMID:21256081; http://dx.doi.org/10.1016/S1470-2045(10)70296-5.
38. Smith SC, Baras AS, Lee JK, Theodorescu D. The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Res 2010; 70:1753-8; PMID:20160033; http://dx.doi. org/10.1158/0008-5472.CAN-09-3562.
39. McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, et al. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 2009; 28:335- 44; PMID:20012924; http://dx.doi.org/10.1007/s10555-009-9194-7.
40. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR- 205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10:593- 601; PMID:18376396; http://dx.doi.org/10.1038/ncb1722.
41. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119:1420- 8; PMID:19487818; http://dx.doi.org/10.1172/ JCI39104.
42. Park BJ, Lee SJ, Kim JI, Lee SJ, Lee CH, Chang SG, et al. Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res 2000; 60:3370- 4; PMID:10910040.
43. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331:1259-64; PMID:7935683; http://dx.doi. org/10.1056/ NEJM199411103311903.
44. Esrig D, Spruck CH, 3rd, Nichols PW, Chaiwun B, Steven K, Groshen S, et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade and stage in bladder cancer. Am J Pathol 1993; 143:1389-97; PMID:7901994.
45. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993; 85:53-9; PMID:7677935; http://dx.doi. org/10.1093/jnci/85.1.53.
46. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 2010; 5:13821; PMID:21072204; http://dx.doi.org/10.1371/journal.pone.0013821.
47. van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boevé ER, Jöbsis AC, et al. FGFR3 and p53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 2004; 64:1911- 4; PMID:15026322; http://dx.doi.org/10.1158/0008-5472.CAN-03-2421.
48. Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 2011; 43:875-8; PMID:21822268; http://dx.doi. org/10.1038/ng.907.
49. Dinney CP, Fishbeck R, Singh RK, Eve B, Pathak S, Brown N, et al. Isolation and characterization of meta-static variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol 1995; 154:1532-8; PMID:7658585; http://dx.doi.org/10.1016/S0022-5347(01)66923-4.
50. Metwalli AR, Khanbolooki S, Jinesh G, Sundi D, Shah JB, Shrader M, et al. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Cancer Biol Ther 2010; 10:885- 92; PMID:20814238; http://dx.doi.org/10.4161/ cbt.10.9.13237.
51. Chow SE, Chang YL, Chuang SF, Wang JS. Wogonin induced apoptosis in human nasopharyngeal carcinoma cells by targeting GSK-3β and ΔNp63. Cancer Chemother Pharmacol 2011; 68:835-45; PMID:21207227; http://dx.doi.org/10.1007/ s00280-010-1552-1.
52. Wright GW, Simon RM. A random variance model for detection of differential gene expression in small micro-array experiments. Bioinformatics 2003; 19:2448-55; PMID:14668230; http://dx.doi.org/10.1093/bioinformatics/ btg345.
53. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009; 69:5820-8; PMID:19584296; http://dx.doi.org/10.1158/0008-5472.CAN-08-2819.